What is Assembly Biosciences?
Assembly Biosciences, Inc. is a clinical-stage biotechnology firm dedicated to the development of innovative oral therapeutics. The company's primary focus is on addressing the unmet medical needs associated with hepatitis B virus (HBV) infection. Additionally, Assembly Biosciences is pioneering a novel class of oral synthetic live biotherapeutics designed to restore health to a dysbiotic microbiome. These efforts position the company at the forefront of developing advanced treatments for significant gastrointestinal and infectious diseases.
How much funding has Assembly Biosciences raised?
Assembly Biosciences has raised a total of $63.4M across 5 funding rounds:
Multiple Rounds
$20.8M
Private Equity
$12.6M
Private Equity
$30M
Debt (2010): $2.7M, investors not publicly disclosed
Debt (2010): $700K, investors not publicly disclosed
Stock Issuance/Offering (2010): $17.4M, investors not publicly disclosed
Private Equity (2024): $12.6M featuring Armistice Capital and Gilead Sciences
Private Equity (2024): $30M backed by Gilead Sciences
Key Investors in Assembly Biosciences
Armistice Capital
Armistice Capital is a global hedge fund employing a long/short, value-oriented, and event-driven investment strategy, primarily targeting the health care and consumer sectors. The firm focuses on generating returns through strategic investments and market opportunities within these industries.
Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need. The company has a broad portfolio including treatments for HIV/AIDS, viral hepatitis, and oncology, and engages in numerous collaboration agreements with other biotech firms.
What's next for Assembly Biosciences?
With the recent influx of major strategic capital, Assembly Biosciences is poised for significant advancement. The enterprise-level funding suggests a transition towards later-stage development and potential commercialization activities. The company is likely to prioritize expanding its clinical trial programs for its HBV therapeutics and advancing its microbiome-based biotherapeutics towards regulatory submission. This strategic investment will also likely bolster research and development efforts, potentially exploring new therapeutic applications and expanding its intellectual property portfolio. The company's trajectory indicates a strong focus on scaling operations and solidifying its market position in the competitive biopharmaceutical landscape.
See full Assembly Biosciences company page
